Mark Rose, MD
Foot Surgery · Natick, MANPI 1790871804
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,600 of the $9,039 with a category attached, or 62.0%. Collagen Matrix, Inc accounts for 62.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $5,676 and has fallen 98.6% since, to $78 in 2023. Among foot surgery clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $231.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collagen Matrix, Inc$6K
- Kairos Surgical Inc$3K
- Smith+Nephew$384
- Teva Pharmaceuticals USA, Inc.$146
- Misonix Inc$86
- Axogen$48
- plus $154 from 6 others
What the payments were for
- Consulting fees$5,60062%
- Food & beverage$8309%
- Education$2,60929%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collagen Matrix, Inc | 1 | $5,600 |
| Kairos Surgical Inc | 5 | $2,622 |
| Smith+Nephew | 12 | $384 |
| Teva Pharmaceuticals USA, Inc. | 10 | $146 |
| Misonix Inc | 1 | $86 |
| Axogen | 2 | $48 |
| Pacira Therapeutics, Inc. | 2 | $48 |
| Stryker | 2 | $38 |
| Osteomed LLC | 1 | $30 |
| Averitas Pharma Inc. | 1 | $20 |
| Acumed LLC | 1 | $11 |
| Organogenesis Inc. | 1 | $7 |
How this compares
$9,039 in reported general payments places this provider in the 95th percentile of 41 foot surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colchicine | 12 | $407 |
| Gabapentin | 14 | $174 |
| Naproxen | 14 | $57 |
| Methylprednisolone | 14 | $48 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Natick
- Michael RobinsonNatick$66
- Philip LukoffNatick$25
- Adam LandsmanBoston$385K
- Jamey AllenWoburn$8K
- Ewald MendeszoonWest Roxbury$6K
- Christopher LockeBoston$6K
- Jurgen FernandezLynn$4K
- Justin OgbonnaBoston$4K
- Neil FeldmanWorcester$4K
- Wei TsengBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.